Stock market today: S&P 500 drops for fifth day as focus shifts to Powell’s speech
Alexis DeSieno, the Chief Financial Officer of Cardlytics, Inc. (NASDAQ:CDLX), recently made a notable transaction involving the company's stock. According to a filing with the Securities and Exchange Commission, DeSieno sold 8,854 shares of Cardlytics stock on January 3, 2025. The shares were sold at a weighted average price of $3.667, amounting to a total transaction value of $32,467. The transaction comes as Cardlytics, currently valued at $179.4 million, has seen its stock decline nearly 6% year-to-date, according to InvestingPro data.
The transaction was conducted to satisfy tax withholding obligations resulting from the vesting of restricted stock units (RSUs) on January 1, 2025. Following this sale, DeSieno holds 121,976 shares of Cardlytics common stock. InvestingPro analysis indicates the company operates with significant debt burden, maintaining a debt-to-equity ratio of 3.18, though its current ratio of 1.18 suggests adequate liquidity to meet short-term obligations.
The RSUs, which convert to common stock on specific vesting dates, are part of a larger award originally comprising 114,796 shares. These units vest in equal installments, with the next vesting scheduled for April 1, 2025, contingent on continued employment with the company. Investors can access comprehensive analysis and additional insights about Cardlytics through the detailed Pro Research Report, available exclusively on InvestingPro.
In other recent news, Cardlytics has shared its third-quarter financial results for 2024, highlighting an optimistic outlook for the forthcoming quarter. The company anticipates improved financial performance in Q4 2024, supported by new financial institution partnerships and operational and product enhancements. Despite these positive projections, Cardlytics has also acknowledged various risk factors that could potentially impact the actual results.
The company's expansion plans include the introduction of new partnerships with financial institutions, which are expected to bolster its market position. Operational and product initiatives are also in the pipeline, aimed at enhancing the company's offerings.
These recent developments underscore Cardlytics' commitment to growth and improvement. However, it's important to note that these forward-looking statements are based on current assumptions and are subject to risks. For a more detailed financial analysis, interested parties can refer to the company's press release and SEC filings available on the Cardlytics website.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.